ghk-cu dosage subcutaneous or topical Guide 2026: mg/Week, Chart & Protocol ghk-cu peptide typical dosage subcutaneous
Description
While the research community eagerly awaits direct clinical trials, the scientific rationale is incredibly strong
LTP of synaptic transmission is blocked by a DOR antagonist, without affecting potentiation of the population spike (Krug et al., 2001)
It is not a substitute for getting new gut symptoms properly diagnosed, and it should never replace 5-ASAs, biologics, immunomodulators, or other established maintenance therapy
updated 2024
However, they may struggle with abstract concepts, inference-making, or learning that requires significant social interaction
